Abbonarsi

The development of an objective method for measuring scratch in children with atopic dermatitis suitable for clinical use - 24/08/11

Doi : 10.1016/S0190-9622(03)02480-0 
Kenneth Benjamin, PhD a, Karen Waterston, BA a, Margaret Russell, RGN a, Olivia Schofield, FRCPE a, Brian Diffey, PhD b, Jonathan L Rees, FMedSci a,
a Systems Group, Department of Dermatology, The University of Edinburgh, Edinburgh, United Kingdom 
b Department of Medical Physics, The University of Newcastle, Newcastle, United Kingdom 

*Reprint requests: Jonathan Rees, FMedSci, Systems Group, Department of Dermatology, University of Edinburgh, Room 4.018, First Floor, Lauriston Bldgs, Lauriston Pl EH3 9YW, UK.

Abstract

Itch is a major symptom of skin disease and remains poorly studied. We have used limb-worn digital accelerometers, and infrared video of patients as a gold standard, on children with atopic dermatitis and control subjects in their own homes at night. Video analysis shows that nocturnal scratching and restlessness are more complex than we first thought, with many movements that potentially damage the skin not conforming to stereotypical scratch movements. Children with atopic dermatitis spent a mean of 46 minutes less time motionless or sleeping at night than control subjects (468 ± 3 [SEM] vs 422 ± 37 [SEM], P < .001). Children with atopic dermatitis showed 2 to 3 times as much scratching or restlessness activity as control subjects, with little overlap between groups (P < .01). Scratching and restlessness were highly correlated with each other (0.94, P < .01). Accelerometer scores were highly correlated with video results (ρ > 0.02, P < .01, for scratching, restlessness, and sleeping time). Individual limb scores were highly correlated with each other (ρ approximately 0.87-0.98), suggesting that little information would be lost if only 1 limb was measured. There was little relation between parental assessment of scratch and objective measured scratch. Accelerometers provide a useful and practical way of assessing scratching at night in the patient's own home and could be used as an objective measure of disease activity both in clinical trials and in everyday clinical practice.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Supported by The Wellcome Trust with additional support from Glaxo SmithKline, Consumer Healthcare, Weybridge, UK.
Disclosure: Prof Rees has consulted for Glaxo SmithKline during the last 5 years on the study of human itch. He has also given paid seminars to other pharmaceutical companies on itch. The current project was partly financed through a research grant to the University of Edinburgh from Glaxo SmithKline.


© 2004  American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 50 - N° 1

P. 33-40 - gennaio 2004 Ritorno al numero
Articolo precedente Articolo precedente
  • Primary cicatricial alopecias: clinicopathology of 112 cases
  • Eileen Tan, Magdalena Martinka, Nigel Ball, Jerry Shapiro
| Articolo seguente Articolo seguente
  • On the move

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.